{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:15:21Z","timestamp":1772014521699,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Empire Health Foundation","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>This report describes a case of likely drug-induced Parkinsonism (DIP) identified by the pharmacist. A 54-year-old female patient was referred by a physician to the pharmacist in a rural, integrated care team for a comprehensive medication review (CMR) to address the patient\u2019s concerns of possible Parkinson\u2019s disease (PD). While PD may occur over the progression of age, medications that affect dopamine transport can also cause DIP, a secondary form of Parkinson\u2019s disease. Although PD and DIP may be clinically indistinguishable, differentiation may be possible by reviewing a patient\u2019s medication history for any potential causative drugs correlating to the timeline of the onset of symptoms. In this case, the pharmacist reviewed the medication profile and identified medications that could be responsible for causing DIP, specifically bupropion. The pharmacist suggested discontinuing bupropion and identifying another option for treating depression. The patient appreciated the suggestion and education, but ultimately preferred continuing her bupropion therapy instead of discontinuing therapy or changing to an alternative agent. At a follow-up meeting with the pharmacist, not only was the patient still experiencing tremors despite taking carbidopa\/levodopa, but additional medications known to be potential inducers of tremors were added to her regimen. Although the pharmacist repeatedly discussed DIP with the patient and believed stopping bupropion would determine whether her Parkinsonism was PD or DIP, ultimately the patient continued taking bupropion because of concerns related to depression severity and the impact on her well-being. The patient\u2019s wishes were respected.<\/jats:p>","DOI":"10.3390\/pharmacy10010010","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T20:21:56Z","timestamp":1641759716000},"page":"10","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Respecting the Patient\u2019s Choice: A Case of Possible Drug-Induced Parkinsonism"],"prefix":"10.3390","volume":"10","author":[{"given":"Megan R.","family":"Undeberg","sequence":"first","affiliation":[{"name":"Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-1311","authenticated-orcid":false,"given":"Kimberly C.","family":"McKeirnan","sequence":"additional","affiliation":[{"name":"Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Easley","sequence":"additional","affiliation":[{"name":"Independent Researcher, Newport, WA 99156, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: Substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"ref_3","unstructured":"(2021, June 12). Is Parkinsonism the Same as Parkinson\u2019s Disease?. Available online: https:\/\/parkinsonsdisease.net\/answers\/parkinsonism-vs-pd."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mds.26839","article-title":"Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study","volume":"32","author":"Savica","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_5","unstructured":"(2021, January 18). Parkinson\u2019s Disease vs. Parkinsonism. Available online: https:\/\/parkinson.org\/pd-library\/fact-sheets\/parkinsonism-vs-parkinsons-disease."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2169\/internalmedicine.2553-18","article-title":"Symptomatic Characteristics of Parkinson\u2019s Disease Induced by Neuroleptic Drugs, Based on a Functional Neuroimaging Diagnosis","volume":"59","author":"Tachibana","year":"2020","journal-title":"Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","article-title":"Drug-induced parkinsonism: A review","volume":"8","author":"Montastruc","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00127893-200211000-00006","article-title":"Drug-induced parkinsonism","volume":"8","year":"2002","journal-title":"Neurologist"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.37901\/jcphp18-00028","article-title":"Implementing pharmacist-led patient home visits","volume":"66","author":"McKeirnan","year":"2019","journal-title":"J. Contemp. Pharm. Pract."},{"key":"ref_11","unstructured":"(2021, June 26). Facts & Comparisons. Available online: https:\/\/fco.factsandcomparisons.com\/lco\/action\/home."},{"key":"ref_12","unstructured":"(2021, June 26). Micromedex 2.0. Available online: https:\/\/www.micromedexsolutions.com\/micromedex2\/4.14.0\/WebHelp\/Tools\/Interactions\/Drug_Interactions.htm."},{"key":"ref_13","first-page":"215","article-title":"Drug-induced Parkinson\u2019s disease. A clinical review","volume":"18","author":"Bohlega","year":"2013","journal-title":"Neurosci. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JPRLS.S99197","article-title":"Drug-induced parkinsonism: Diagnosis and management","volume":"6","author":"Blanchet","year":"2016","journal-title":"J. Parkinsonism Restless Legs Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: A review of 17 years\u2019 experience in a regional pharmacovigilance center in France","volume":"26","author":"Bagheri","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-020-02711-z","article-title":"Antidepressants and movement disorders: A postmarketing study in the world pharmacovigilance database","volume":"20","author":"Revet","year":"2020","journal-title":"BMC Psychiatry"},{"key":"ref_17","first-page":"VD01","article-title":"A Case of SSRI Induced Irreversible Parkinsonism","volume":"9","author":"Dixit","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors","volume":"57","author":"Leo","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"ref_19","first-page":"243","article-title":"Parkinsonism secondary to duloxetine use: A case report","volume":"2","author":"Bayrak","year":"2015","journal-title":"North. Clin. Istanb."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.17302","article-title":"Selective serotonin-reuptake inhibitor-induced movement disorders","volume":"32","author":"Gerber","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.74.1.137","article-title":"Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran","volume":"74","author":"Arai","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-2006-951608","article-title":"Dyskinesia during treatment with duloxetine","volume":"39","author":"Deuschle","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/pcn.12017","article-title":"Venlafaxine-related akathisia side-effects and management in a depressed patient","volume":"67","author":"Lai","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson\u2019s disease: An update on non-motor symptoms and investigations","volume":"20","author":"Brigo","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_25","unstructured":"AHRQ (2021, December 20). The Share Approach: A Model for Shared Decisionmaking\u2014Fact Sheet, Available online: https:\/\/www.ahrq.gov\/health-literacy\/professional-training\/shared-decision\/tools\/factsheet.html."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jep.13246","article-title":"Shared decision-making in outpatients with mental disorders: Patients\u2019 preferences and associated factors","volume":"25","year":"2019","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40271-019-00383-w","article-title":"The Shared Decision-Making Process in the Pharmacological Management of Depression","volume":"13","author":"Hopwood","year":"2020","journal-title":"Patient-Patient-Cent. Outcomes Res."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/1\/10\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:59Z","timestamp":1760362019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/1\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmacy10010010"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy10010010","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}